Literature DB >> 1530957

Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus.

H G Rus1, L M Kim, F I Niculescu, M L Shin.   

Abstract

Synthesis of complement proteins and their regulation in resident cells of the central nervous system are important pathophysiologic factors that can affect the outcome of inflammatory central nervous system diseases. Primary cultures of rat astrocytes constitutively express C3 mRNA and produce C3 protein; both of them were enhanced by LPS or by a live as well as inactivated Newcastle disease virus, a neurotropic paramixovirus. TNF, IL-1 beta, and IL-8 also increased the levels of C3 mRNA and protein whereas IL-1 alpha and IL-6 had no effect, although all of these cytokines are inducible by LPS. LPS stimulation in the presence of cycloheximide decreased the LPS-mediated C3 mRNA induction by 60%. These data suggest that LPS effect on C3 regulation is mediated directly by LPS as well as by LPS-induced cytokines. Interestingly, C3 mRNA induced by Newcastle disease virus or inactivated Newcastle disease virus was inhibited by protein kinase inhibitors, H-7 and staurosporine, whereas these inhibitors had no effect on C3 induction mediated by LPS or cytokines, indicating the existence of different signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530957

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons.

Authors:  Cornelia Speth; Thomas Schabetsberger; Iradji Mohsenipour; Gabriele Stöckl; Reinhard Würzner; Heribert Stoiber; Cornelia Lass-Flörl; Manfred P Dierich
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes.

Authors:  C Speth; G Stöckl; I Mohsenipour; R Würzner; H Stoiber; C Lass-Flörl; M P Dierich
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 3.  The complement system in central nervous system diseases.

Authors:  H Rus; F Niculescu
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

Authors:  S K Singhrao; J W Neal; N K Rushmere; B P Morgan; P Gasque
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

Review 5.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

6.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

7.  Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer's patients.

Authors:  B Fischer; H Schmoll; P Riederer; J Bauer; D Platt; A Popa-Wagner
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

8.  Role of Activated Glia and of Glial Cytokines in Alzheimer's Disease: A Review.

Authors:  R E Mrak; W St Griffin
Journal:  EOS       Date:  1996

9.  RGC-32 regulates reactive astrocytosis and extracellular matrix deposition in experimental autoimmune encephalomyelitis.

Authors:  Alexandru Tatomir; Cosmin A Tegla; Alvaro Martin; Dallas Boodhoo; Vinh Nguyen; Adam J Sugarman; Armugam Mekala; Freidrich Anselmo; Anamaria Talpos-Caia; Cornelia Cudrici; Tudor C Badea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.